B&K CORP-B (02396) has announced that the Phase IIIa clinical trial for Pro-101-1, a product developed by the company for the treatment of deep second-degree burns, has recently completed enrollment of its first patient. Pro-101-1 is one of the company's core products. This clinical trial is a randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating deep second-degree burn wounds. The trial will also provide key parameters for the design of the subsequent Phase IIIb clinical trial, involving a large number of enrolled subjects. The completion of the first patient enrollment for the Pro-101-1 Phase IIIa trial represents another significant research and development advancement for the company in the field of burn and scald treatment.